Diamyd Medical AB (publ)
Research Diamyd Medical AB (publ) (DMYD-B) on Bullrun: market cap SEK 141.35M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerDMYD-B
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencySEK
- Market capSEK 141.35M
- Financial periodQ1 2026
- RevenueSEK 99.00K
- Net income-SEK 62.88M
- Free cash flow-SEK 39.68M
- Gross margin-693.9%
Valuation Snapshot
latest market cap is SEK 141.35M.
About Diamyd Medical AB (publ)
Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA); and Remygen, an immunomodulation therapy, that is in phase I/II clinical trial for the treatment of with type 1 diabetes, type 2 diabetes, and LADA.
Frequently asked questions
What is Diamyd Medical AB (publ)'s market cap?
Diamyd Medical AB (publ)'s market capitalization is SEK 141.35M.
What does Diamyd Medical AB (publ) do?
Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA);